Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Anavex Life Sciences Corp.NASDAQ: AVXL

Gross Profit · Q1 FY2026 · quarter ended Dec 2025

Gross profit remains negative

Q1 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was $0.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearSep 2025
$0— YoY
LTMDec 2025
$0— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
AVXL Competitors
Gross Profit for AVXL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARVNArvinas, Inc.LTM Mar 2026$87.1M USD-79.5%+25.1%97.4%
MGTXMeiraGTx Holdings plcLTM Mar 2026$73.09M USD+682.6%+68.8%91.6%
VALNValneva SELTM Mar 2026€46.05M EUR-46.8%+22.4%29.5%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$35.29M USD-76.1%+12.8%99.3%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 USD———
RGNXREGENXBIO Inc.LTM Mar 2026-$120K USD-100.1%+37.2%0.1%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$124K USD-24.0%——
ERASErasca, Inc.LTM Sep 2026-$1.47M USD-76.2%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$2.34M USD-7090.5%——
ABSIAbsci CorporationLTM Mar 2026-$24.18M USD+48.7%—1316.9%
Peer median (excluding AVXL) —-76.1%+25.1%94.5%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development32.98M37.92M43.72M41.84M37.59M
Selling, General & Admin9.02M13.07M12.05M11.04M13.82M
Operating Expenses42M50.99M55.76M52.88M51.41M
Depreciation & Amortization00000
EBITDA(37.64M)(47.62M)(46.54M)(43M)(46.38M)
EBITDA Margin—————
Operating Income(42M)(50.99M)(55.76M)(52.88M)(51.41M)
Operating Margin—————
Interest Income26K947K6.52M7.32M4.68M
Interest Expense00964K00
Other Income / Expenses4.36M3.37M8.26M9.88M5.03M
Income Before Tax(37.64M)(47.62M)(47.51M)(43M)(46.38M)
Pre-Tax Margin—————
Income Tax Expense268K358K000
Net Income(37.91M)(47.98M)(47.51M)(43M)(46.38M)
Net Margin—————
EPS (Basic)(0.54)(0.62)(0.60)(0.52)(0.54)
EPS (Diluted)(0.54)(0.62)(0.60)(0.52)(0.54)
Weighted Avg Shares69.8M76.91M79.79M83.47M85.29M
Weighted Avg Shares (Diluted)69.8M76.91M79.79M83.47M85.29M

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.